SS-31 (Elamipretide, MTP-131) is a mitochondria-targeting tetrapeptide studied for its cardioprotective and neuroprotective properties. It has been evaluated in Phase II clinical trials for heart failure with preserved ejection fraction (HFpEF) and mitochondrial myopathy, providing more robust safety data than many research peptides. This review summarizes the adverse effects observed in available research.
Research Use Only: This information is for educational and research purposes only. SS-31 is not FDA-approved for human use. Consult a qualified healthcare professional before any use.
SS-31 selectively targets cardiolipin on the inner mitochondrial membrane, stabilizing mitochondrial cristae structure and reducing reactive oxygen species (ROS) production. This mechanism of action is distinct from most other research peptides and contributes to its favorable safety profile.
Injection site reactions including pain, erythema, and bruising are the most commonly reported adverse effects in clinical trials of SS-31. These are generally mild and transient.
Mild fatigue has been reported in some clinical trial participants, though this may be difficult to distinguish from disease-related fatigue in the populations studied.
Mild headaches have been reported in a subset of clinical trial participants.
Mild nausea has been reported in some clinical trial participants, typically transient and not requiring discontinuation.
Mild dizziness has been reported in some participants in SS-31 clinical trials.
Mild blood pressure reduction has been observed in some research subjects, consistent with SS-31's vasodilatory effects.
SS-31 has been evaluated in Phase II clinical trials and demonstrated a generally favorable safety profile. The TOPCAT and MMPOWER-3 trials provided substantial human safety data. It is not FDA-approved for human use and should only be used in legitimate research settings.
Yes. SS-31 (Elamipretide) has been evaluated in Phase II clinical trials including TOPCAT (heart failure) and MMPOWER-3 (mitochondrial myopathy), providing substantial human safety data.
SS-31 demonstrated a generally favorable safety profile in Phase II clinical trials. It is not FDA-approved for human use and should only be used in legitimate research settings.
Mild blood pressure reduction has been observed in some research subjects, consistent with SS-31's vasodilatory effects. Research subjects with hypotension should be monitored.
SS-31 has been studied in heart failure populations who were often on multiple cardiac medications. No significant drug interactions were identified in clinical trials, but caution is warranted.
Purgo Labs provides research-grade SS-31 with third-party HPLC and mass spectrometry verification from accredited US laboratories. Every batch ships with a full Certificate of Analysis.
Shop SS-31 at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.